Ausgabe 3/2022
Inhalt (15 Artikel)
Antibody–Drug Conjugates in Uro-Oncology
Dawid Sigorski, Paweł Różanowski, Ewa Iżycka-Świeszewska, Katarzyna Wiktorska
Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review
Thomas D. McLean, Serena Duchi, Claudia Di Bella
When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents
Daniel V. Araujo, Bruno Uchoa, Juan José Soto-Castillo, Larissa L. Furlan, Marc Oliva
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study
Abdulazeez Salawu, Aaron R. Hansen, Anna Spreafico, Esmail Al-Ezzi, Sheila Webster, Philippe L. Bedard, Jeffrey Doi, Lisa Wang, Lillian L. Siu, Albiruni R. Abdul Razak
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study
Tanya Trippett, Helen Toledano, Quentin Campbell Hewson, Arnauld Verschuur, Anne-Marie Langevin, Isabelle Aerts, Lisa Howell, Soledad Gallego, Claudia Rossig, Amy Smith, Darshak Patel, Leonardo R. Pereira, Sravanthi Cheeti, Luna Musib, Katherine E. Hutchinson, Clare Devlin, Ronald Bernardi, Birgit Geoerger
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Gee-Chen Chang
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi
Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
Andrew J. Klink, Abhishek Kavati, Awa T. Gassama, Tom Kozlek, Ajeet Gajra, Ruth Antoine
Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor
Laura C. Kennedy, Jun Lu, Sydney Kuehn, Arturo B. Ramirez, Edward Lo, Yao Sun, Lance U’Ren, Laura Q. M. Chow, Zhengjia Chen, Petros Grivas, Eric P. Kaldjian, Vijayakrishna K. Gadi
Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy
Takuro Mizukami, Masaki Takahashi, Yu Sunakawa, Satoshi Yuki, Yoshinori Kagawa, Atsuo Takashima, Kyoko Kato, Hiroki Hara, Tadamichi Denda, Yoshiyuki Yamamoto, Manabu Shiozawa, Eiji Oki, Wataru Okamoto, Takayuki Yoshino, Takako Eguchi Nakajima
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Joan R. E. Choo, Yi-Hua Jan, Samuel G. W. Ow, Andrea Wong, Matilda Xinwei Lee, Natalie Ngoi, Kritika Yadav, Joline S. J. Lim, Siew Eng Lim, Ching Wan Chan, Mikael Hartman, Siau Wei Tang, Boon Cher Goh, Hon Lyn Tan, Wan Qin Chong, Ang Li En Yvonne, Gloria H. J. Chan, Shu-Jen Chen, Kien Thiam Tan, Soo Chin Lee
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC
James E. Frampton
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V. Faller, lwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-pyo Kim
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Lesley J. Scott